AR061280A1 - Utilizacion de la gonadotrofina corionica humana por via oral o inyectable en el tratamiento del sindrome metabolico - Google Patents

Utilizacion de la gonadotrofina corionica humana por via oral o inyectable en el tratamiento del sindrome metabolico

Info

Publication number
AR061280A1
AR061280A1 ARP070105510A ARP070105510A AR061280A1 AR 061280 A1 AR061280 A1 AR 061280A1 AR P070105510 A ARP070105510 A AR P070105510A AR P070105510 A ARP070105510 A AR P070105510A AR 061280 A1 AR061280 A1 AR 061280A1
Authority
AR
Argentina
Prior art keywords
metabolic syndrome
treatment
syndrome
gonadotrophin
injectable
Prior art date
Application number
ARP070105510A
Other languages
English (en)
Inventor
Daniel Oscar Belluscio
Original Assignee
Daniel Oscar Belluscio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daniel Oscar Belluscio filed Critical Daniel Oscar Belluscio
Priority to ARP070105510A priority Critical patent/AR061280A1/es
Publication of AR061280A1 publication Critical patent/AR061280A1/es
Priority to US12/314,719 priority patent/US20090156468A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El síndrome metabolico (SM) conocido también como síndrome plurimetabolico, síndrome de resistencia a la insulina o síndrome X- es una entidad clínica que aparece con amplias variaciones fenotípicas en personas con una predisposicion endogena, determinada genéticamente y condicionada por factores ambientales. Consiste en el uso de la Gonadotrofina Corionica Humana por vía oral o inyectable para el tratamiento del síndrome metabolico y está destinada al tratamiento de pacientes con cuadro de uno o varios de los síntomas clínicos o análisis de laboratorio siguientes: hipertension arterial, diabetes tipo 2, hiperglucemias reactivas, niveles altos de triglicéridos plasmáticos, cifras de colesterol alto, enfermedad gotosa cuando acompana al síndrome metabolico.
ARP070105510A 2007-12-07 2007-12-07 Utilizacion de la gonadotrofina corionica humana por via oral o inyectable en el tratamiento del sindrome metabolico AR061280A1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ARP070105510A AR061280A1 (es) 2007-12-07 2007-12-07 Utilizacion de la gonadotrofina corionica humana por via oral o inyectable en el tratamiento del sindrome metabolico
US12/314,719 US20090156468A1 (en) 2007-12-07 2008-12-16 Use of human chorionic gonadotropin oral or injectable for metabolic syndrome treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP070105510A AR061280A1 (es) 2007-12-07 2007-12-07 Utilizacion de la gonadotrofina corionica humana por via oral o inyectable en el tratamiento del sindrome metabolico

Publications (1)

Publication Number Publication Date
AR061280A1 true AR061280A1 (es) 2008-08-20

Family

ID=39722441

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105510A AR061280A1 (es) 2007-12-07 2007-12-07 Utilizacion de la gonadotrofina corionica humana por via oral o inyectable en el tratamiento del sindrome metabolico

Country Status (2)

Country Link
US (1) US20090156468A1 (es)
AR (1) AR061280A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR058438A1 (es) * 2006-07-21 2008-02-06 Daniel Oscar Belluscio Utilizacion de la gonadotrofina corionica humana por via oral para el tratamiento del sobrepeso (obesidad) asociado a hipertension arterial, diabetes no insulino dependiente, hipercolesterolemia, dislipemias y lipodistrofias
WO2013102921A2 (en) * 2011-11-17 2013-07-11 Sanzyme Limited Hcg - newer treatment modality for type 2 diabetes mellitus (t2dm)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006079056A1 (en) * 2005-01-20 2006-07-27 Stephen Holt Herbal compositions containing hoodia
US7605122B2 (en) * 2005-07-29 2009-10-20 Millennium Medical Spa Human chorionic gonadotropin (hCG) formulations for facilitating weight loss and body contouring

Also Published As

Publication number Publication date
US20090156468A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
Eslamparast et al. Sarcopenic obesity in cirrhosis—the confluence of 2 prognostic titans
Chen et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies
Hodes et al. Disease drivers of aging
Perreault et al. Approaching pre-diabetes
Ramírez et al. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
Sonthalia et al. Etiopathogenesis of melasma
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
WO2008013863A3 (en) Generation of adipose tissue and adipocytes
Vaarala et al. Should we treat infection or inflammation to prevent T2DM?
Towler Mitochondrial ROS deficiency and diabetic complications: AMP [K]-lifying the adaptation to hyperglycemia
Liu et al. Ageing and type 2 diabetes in an elderly Chinese population: the role of insulin resistance and beta cell dysfunction
AR061280A1 (es) Utilizacion de la gonadotrofina corionica humana por via oral o inyectable en el tratamiento del sindrome metabolico
JP2008528043A5 (es)
Chhabra et al. Gallbladder disease in type-2 Diabetes mellitus patients.
Shanthala et al. The effect of thermocycling on fracture toughness and hardness of different core build up materials
Dymicka-Piekarska et al. Soluble P-selectin concentration in patients with colorectal cancer.
Chan A clinical data mining study of the psychosocial status of Chinese cancer patients in palliative care
ES2489016T3 (es) Acetaminofeno glucuronidado como un marcador de trastornos hepáticos
Mohammed et al. The potential effect of metformin therapy on neutrophil-lymphocyte ratio in patients with type II diabetes mellitus: A new horizon
Saprina et al. The associations of incretin hormone concentration with gestational diabetes mellitus
BR112013032132A2 (pt) "uso de peptidase da família calicreína, de agente que aumenta a sua expressão ou de células que apresentam expressão ou atividade de rheb reduzida para prevenção ou tratamento de diabetes e distúrbio metabólico e aumento da sensibilidade à insulina, bem como métodos para determinar se composto de teste é agente terapêutico provável no tratamento de diabetes"
Soliman et al. Association of Circular RNA 0068087 Expression Level with Cardiovascular Risk Factors in Patients with or without Type 2 Diabetes Mellitus
Giese Adult diabetes mellitus: Thinking beyond type 2
Suman et al. A Comparative Study of Acute-On-Chronic Liver Failure (ACLF) Patients with Respect to Diabetes Mellitus and Metabolic Syndrome.
Shen Detecting prediabetes using an oral insulin-glucose tolerance test in nonalcoholic fatty liver disease patients without diabetes

Legal Events

Date Code Title Description
FB Suspension of granting procedure